Projects per year
Personal profile
Biography
Dr. Lim is an early career postdoctoral fellow in the Precision Cancer Therapy (PCT) group at Macquarie University, and she is currently investigating the transcriptomic and proteomic profiles of melanoma patients treated with selective kinase inhibitors and immunotherapy. Her overarching research goal is to delineate mechanisms of immune responses and translate these findings to clinical applications, particularly in improving immunotherapy efficacy.
Dr. Lim has had over 7 years cancer research experience with a focus on cancer cell biology and tumour immunology. She was previously appointed as a postdoctoral researcher at the University of Oxford (from 2011-2015), and her past studies defined pro-metastatic activity of immune cells in sustaining liver metastasis of colorectal cancer. These findings provided valuable insights into the role of the host immune system in cancer progression and were published in Hepatology (2011 and 2013) and Oncogene (2016).
Dr. Lim graduated from the University of New South Wales with a PhD degree in Pathology, and her postgraduate research elucidated how oxidative modifications of inflammatory proteins regulate immune responses, and were published in the Journal of Immunology (2008) and Journal of Biological Chemistry (2010). Prior to her PhD, Dr. Lim undertook an Honours project in her final undergraduate year, on the production and characterization of monoclonal antibodies against the chloride intracellular channel 1 (CLIC1) protein, and was awarded first class honours. In the interim of commencing her PhD degree, she worked as a research assistant in close collaboration with industrial research partners and was involved in the production of specific monoclonal antibodies under cGMP conditions for use in Phase I clinical trials.
Education/Academic qualification
Pathology, PhD, The University of New South Wales
2006 → 2010
Biotechnology, Bachelor of Science, The University of New South Wales
Fingerprint Dive into the research topics where Esther Lim is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 13 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2017 2018
Differential effects of MAPK inhibition on immune activity determine melanoma response
Lim, S. Y., Rizos, H. & Kefford, R.
17/04/17 → …
Project: Research
Establishing an advanced platform for single cell fluorescent imaging and analysis
Morsch, M., Yang, S., Lee, A., Lim, S. Y., Chung, R., Blair, I., Rizos, H. & Atkin, J.
1/01/18 → 31/12/18
Project: Other
Research Outputs 2008 2019
Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1 based immunotherapy
Lim, S. Y., Lee, J. H., Nur Gide, T., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., Scolyer, R. A., Long, G. V. & Rizos, H., Mar 2019, In : Clinical Cancer Research. 25, 5, p. 1557-1563 7 p.Research output: Contribution to journal › Article › Research › peer-review
Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy
Gide, T. N., Quek, C., Menzies, A. M., Tasker, A. T., Shang, P., Holst, J., Madore, J., Lim, S. Y., Velickovic, R., Wongchenko, M., Yan, Y., Lo, S., Carlino, M. S., Guminski, A., Saw, R. P. M., Pang, A., McGuire, H. M., Palendira, U., Thompson, J. F., Rizos, H. & 5 others , 11 Feb 2019, In : Cancer Cell. 35, 2, p. 238-255.e6 24 p.Research output: Contribution to journal › Article › Research › peer-review
Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients
Lee, H., Quek, C., Silva, I., Tasker, A., Batten, M., Rizos, H., Lim, S. Y., Nur Gide, T., Shang, P., Attrill, G. H., Madore, J., Edwards, J., Carlino, M. S., Guminski, A., Saw, R. P. M., Thompson, J. F., Ferguson, P. M., Palendira, U., Menzies, A. M., Long, G. V. & 2 others , Feb 2019, In : OncoImmunology. 8, 2, p. 1-10 10 p., e1537581.Research output: Contribution to journal › Article › Research › peer-review
Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: a rationale for combination inhibitors
Ming, Z., Lim, S. Y., Kefford, R. F. & Rizos, H., 13 Sep 2019, In : Pigment Cell and Melanoma Research. 13 p.Research output: Contribution to journal › Article › Research › peer-review
Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia
Kim, H. Y., Duong, J. K., Gonzalez, M., Long, G. V., Menzies, A. M., Rizos, H., Lim, S. Y., Lee, J. & Boddy, A. V., 8 Apr 2019, In : Cancer Chemotherapy and Pharmacology. 83, 4, p. 693-704 12 p.Research output: Contribution to journal › Article › Research › peer-review